← All Eyepoint Pharmaceuticals, INC filings

Eyepoint Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
10-K: EyePoint's DURAVYU Advances to Phase 3 Amidst Rising Losses
EyePoint, Inc. reports a net loss of $232.0 million for fiscal year 2025, driven by increased R&D for its lead candidate DURAVYU, which is progressing in Phase 3 trials for wet AMD and DME.
NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
10-K: EyePoint Pharmaceuticals Reports 2024 Results, Highlights DURAVYU Progress
EyePoint Pharmaceuticals' 10-K filing details the company's financial performance, DURAVYU's clinical advancements, and strategic outlook.
NASDAQ
EYPT
Eyepoint Pharmaceuticals, INC
10-K: EyePoint Pharmaceuticals Details Common Stock and Regulatory Landscape in 10-K Filing
EyePoint Pharmaceuticals' 10-K filing outlines details of their common stock, regulatory environment, and clinical development programs, including EYP-1901.